

CORRECTION

Open Access



Correction to: Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma

Veronika Kremer¹, Maarten A. Ligtenberg², Rosa Zendejdel¹, Christina Seitz³, Annet Duivenvoorden¹, Erik Wennerberg⁴, Eugenia Colón^{5,6}, Ann-Helén Scherman-Plogell⁷ and Andreas Lundqvist^{1,8*}

Unfortunately, after publication of this article [1], it was noticed that the name of Maarten A. Ligtenberg was displayed incorrectly as Maarten Ligtenberg. The correct author list can be seen above and the original article has been updated to reflect this.

Author details

¹Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. ²Department of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands. ³Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. ⁴Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA. ⁵Department of Oncology-Pathology, Stockholm South General Hospital, Stockholm, Sweden. ⁶Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden. ⁷Department of Urology, Stockholm South General Hospital, Stockholm, Sweden. ⁸Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL, USA.

Received: 10 October 2017 Accepted: 10 October 2017

Published online: 06 November 2017

Reference

1. Kremer V, Ligtenberg M, Zendejdel R, Seitz C, Duivenvoorden A, Wennerberg E, Lundqvist A. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. *Journal for ImmunoTherapy of Cancer*. 2017;5:73. <https://doi.org/10.1186/s40425-017-0275-9>.

* Correspondence: Andreas.lundqvist@ki.se

¹Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

⁸Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL, USA